Antisense Oligonucleotide for Spinal Muscular Atrophy
study id #: NCT05187260
condition: Spinal Muscular Atrophy
status: Not yet recruiting
purpose:This is a longitudinal, multiple-center, observational study of patients genetically confirmed chromosome 5q SMA to monitor the efficacy, safety, tolerability of SPINRAZA® (nusinersen) for up to 24 months.
intervention: Nusinersen
results: https://clinicaltrials.gov/ct2/show/results/NCT05187260
last updated: February 04, 2022
-
Learning Center Progress in Spinal Muscular Atrophy Managementhttps://sma.elsevierresource.com/sites/s...
-
George Z. Mentis, PhDGeorge Mentis received pursued B.Sc in P...
-
Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part ...Background: Risdiplam is an oral small m...
-
The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySpinal muscular atrophy (SMA) is a rare,...
-
Biogen Exercises Option With Ionis to Develop and Commercialize Investigational ASO for SMABiogen, Inc. and Ionis Pharmaceuticals, ...
-
Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated With NusinersenObjective: To retrospectively evaluate t...
-
FDA-Approved Treatment Provides Life-Saving Miracle for Girl With Spinal Muscular AtrophyAlex says her daughter made it to Norton...